OPHELIA
OFFICIAL TITLE: EFFECTIVENESS OF OLAPARIB PLUS TRASTUZUMAB IN HER2-POSITIVE BRCA-MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) ADVANCED BREAST CANCER PATIENTS.
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
ESMO 2019 – DOWNLOAD THE POSTER
SABCS 2022 – DOWNLOAD THE POSTER
CLINICAL TRIAL DETAILS
THE OPHELIA STUDY IS A MULTICENTER, OPEN-LABEL, SINGLE-ARM, TWO COHORTS, SIMON’S TWO-STAGE MINIMAX DESIGN, PHASE II CLINICAL TRIAL.
​
THE PRIMARY OBJECTIVE OF THIS TRIAL IS TO ASSESS THE EFFICACY – AS DETERMINED BY THE OVERALL RESPONSE RATE (ORR) AND PROGRESSION-FREE SURVIVAL (PFS) BASED ON RECIST V.1.1 – OF OLAPARIB IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE, GERMINAL BRCA1/2 MUTATED ABC.
​
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
BREAST
II
33
17
Spain
Closed
OPHELIA SITES
SPAIN
Hospital Arnau de Vilanova de Valencia
SPAIN
Complejo Hospitalario de Jaén
SPAIN
Hospital Universitario Virgen del Rocío
SPAIN
Onkologikoa
SPAIN
Hospital Clínico San Carlos
SPAIN
Hospital Son Llatzer
SPAIN
Hospital Universitario Virgen de la Victoria
SPAIN
Hospital Universitari Son Espases
SPAIN
Hospital Universitari Vall D'Hebron
SPAIN
Hospital Universitario Arnau de Vilanova de Lleida
SPAIN
Complejo Hospitalario Universitario de Santiago (CHUS)
SPAIN
Hospital San Pedro de Alcántara
SPAIN
Complejo Asistencial de Ávila
SPAIN
Hospital Clínico Universitario de Valencia
SPAIN
Hospital Universitario Reina Sofía
SPAIN
Hospital Universitario Ramón y Cajal
SPAIN
Hospital Universitario La Paz